ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2910

Comparison of Clinical and Ultrasound Measures of Disease Activity  in a Large National ‘Real Life’ Cohort of RA Patients

Pascal Zufferey1, Delphine Couvoisier2, Hans Ruedi Ziswiler3, Laure Brulhart4, Giorgio Tamborrini5, Michael Nissen6, Adrian Ciurea7, Burkhard Moeller8, Maria Antonietta D'Agostino9,10 and Axel Finckh2, 1Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, 2geneva university hospital, Geneva, Switzerland, 3Osteorheuma, Bern, Switzerland, 4médecine, hôpital neuchateulois, La chaux de fond, Switzerland, 5UZR, Basel, Switzerland, 6rheumatology, geneva university hospital, Geneva, Switzerland, 7Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 8Department for Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland, 9Department of Rheumatology, Assistance publique-Hôpitaux de Paris Ambroise Paré Hospital, Boulogne-Billancourt , Université Versailles Saint Quentin en Yvelines, Paris, France, 10University of Paris, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Data analysis, Disease Activity, Evaluation, joint procedures and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 8, 2017

Title: Rheumatoid Arthritis – Clinical Aspects VI: Comorbidities of Rheumatoid Arthritis

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Clinical measures of disease activity, such as the DAS-score and ultrasound (US) scores of disease activity can be sometimes yield discordant results. Little research has attempted to understand the reasons for these discordances. Moreover, it is not well known what the implications of such discordances are or how clinical and US assessments evolve over time in this situation

Objectives :First: to determine the percentages of patients presenting discordances between DAS and US assessments in a real-life cohort. Second: to describe associated factors. Third: to evaluate the evolution of both measures of disease activity over time.

Methods: All patients with at least one concomitant US- and DAS-score assessment, performed since the introduction of validated US (SONAR) score in the SCQM between 2009 and January 2017 were included. Disease activity was categorized as remission, low, moderate and high activity based on previously established cut-offs for the DAS and the US-score. Potential predictors of discordance were extracted from the SCQM database, including age, gender, seropositivity, duration of illness, number of swollen and tender joints, global physician assessment of disease activity, HAQ, presence of fibromyalgia, type of treatment, patients followed in private practice and other. A longitudinal analysis was performed in all the patients with at least two subsequent visits with US and DAS assessment performed simultaneously

Results: 2367 assessments could be analyzed, of which 1072 (45%) were considered concordant based on identical disease activity states with the DAS- and the US score. The proportion concordant assessments significantly differed by clinical disease status (p<0.001); more frequent in clinical remission (78.4% of agreement) compared to active disease status (21% in low or moderate DAS, 45% in high DAS). Among the discordant assessments, disease activity state tended to be more frequently over-estimated by the DAS compared to US-score (38%), than the other way round (17%), (p<0.05) .

Factors associated with the presence of discordant results were the swollen joint count (p <0.001), the overall estimation of the disease activity (p<0.001) by the clinician, the duration of the disease (p<0.02)

For 1181 patients, several DAS and US assessments were available during follow-up. The proportion of discordances during the follows up was similar to the initial evaluation. Initial discordance/concordances could however change status without obvious reason, especially in the moderate and low disease activity subgroup (75 % new discordances).

Conclusion: Discordances between DAS and US assessments appear to be higher than expected in real life. Both outcome measures can lead to over- or under-estimations of the true disease activity, Discordant assessments seem to be linked essentially to inaccuracies in the clinical evaluation in particular (inadequate swollen joint counts) and /or to limitations of the US procedure (especially poor distinction between moderate and low activity disease


Disclosure: P. Zufferey, None; D. Couvoisier, None; H. R. Ziswiler, None; L. Brulhart, None; G. Tamborrini, None; M. Nissen, None; A. Ciurea, None; B. Moeller, None; M. A. D'Agostino, None; A. Finckh, None.

To cite this abstract in AMA style:

Zufferey P, Couvoisier D, Ziswiler HR, Brulhart L, Tamborrini G, Nissen M, Ciurea A, Moeller B, D'Agostino MA, Finckh A. Comparison of Clinical and Ultrasound Measures of Disease Activity  in a Large National ‘Real Life’ Cohort of RA Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/comparison-of-clinical-and-ultrasound-measures-of-disease-activity-in-a-large-national-real-life-cohort-of-ra-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-clinical-and-ultrasound-measures-of-disease-activity-in-a-large-national-real-life-cohort-of-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology